ActivistsInvestorsTrumpPoliticiansSerenityCitriniBurrySemianalysisSwingTradeArbitrageSearch

$IMA:NASDAQ · Imax Corp - US

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.

More about this company

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Sector: health

Conviction from: NASDAQ

52-week range: 3.137.89

2 tracked filer(s) hold this · 1 opened, 0 added, 1 trimmed in 30-SEP-2026

Aggregate 13FScore 68 — mean of 2 scored holder(s) · buyers (new/add) avg 61. Higher = the smart money in this name has the better track record.

Filer13FScoreThis quarterSharesValue% of their book
Paul Tudor Jones / Tudor61New buy73,502$4,027,9100.0%
Steve Cohen / Point7275Trimmed -14%380,000$20,824,0000.0%

Beyond 13F — activists, insiders, politicians & research

Activist 13D filings daily digest →

FiledFormActivist% of classConviction
2026-04-29SCHEDULE 13D/AORBIMED ADVISORS LLC13.1%Highfiling
2026-04-21SCHEDULE 13DOmega Fund VI, L.P.8.4%Medfiling

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.